News | May 18, 2025
Alivus Life Sciences reports Q4 FY25 PAT at Rs. 141.86 Cr
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
EBITDA margins expand to 31.3%
Subscribe To Our Newsletter & Stay Updated
